Literature DB >> 18487848

Herpes simplex virus type 1 in Alzheimer's disease: the enemy within.

Ruth F Itzhaki1, Matthew A Wozniak.   

Abstract

Alzheimer's disease is a modern scourge and is likely to become increasingly so in the future, with increasing longevity. The disease has been investigated for over one hundred years yet its causes and that of the neuropathological characteristics seen in AD brain are still completely unknown. Evidence for a major causative role of a common virus, herpes simplex virus type 1 (HSV1), acting in combination with a genetic factor - the type 4 allele of the apolipoprotein gene, a known susceptibility factor - is presented here. The characteristics of the virus, some of which make it an especially likely candidate for this role, are described, as are the many precedents for the action of a genetic factor modulating outcome of infection. Various possible ways in which HSV1 might lead to development of AD, such as its up-regulation of various enzymes and in particular certain kinases, its effect on the cell cycle, on autophagy, and its inflammatory and oxidative effects are also discussed. It is concluded that there is strong evidence that the virus is indeed a major factor in AD and therefore there is a strong case for appropriate treatment, and possibly for prevention in the future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487848     DOI: 10.3233/jad-2008-13405

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  60 in total

Review 1.  Herpes simplex virus type 1 persists in the aged brain through hypothetical expression of accessory genes.

Authors:  Isamu Mori
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  VP16 serine 375 is a critical determinant of herpes simplex virus exit from latency in vivo.

Authors:  Nancy M Sawtell; Steven J Triezenberg; Richard L Thompson
Journal:  J Neurovirol       Date:  2011-12-06       Impact factor: 2.643

3.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

4.  Antiviral agents in Alzheimer's disease: hope for the future?

Authors:  Matthew A Wozniak; Ruth F Itzhaki
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

5.  Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency.

Authors:  Richard L Thompson; Nancy M Sawtell
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 6.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

Review 7.  Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  Clive Holmes; Darren Cotterell
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

8.  Increased risk of dementia among chronic osteomyelitis patients.

Authors:  C-H Tseng; W-S Huang; C-H Muo; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-07       Impact factor: 3.267

9.  Could lysine supplementation prevent Alzheimer's dementia? A novel hypothesis.

Authors:  Robert N Rubey
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-27       Impact factor: 2.570

Review 10.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.